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Abstract
Immunostimulatory therapy is a promising approach to improving the treatment of systemic fungal infections such as
paracoccidioidomycosis (PCM), whose drug therapy is usually prolonged and associated with toxic side effects and relapses.
The current study was undertaken to determine if the injection of a T helper (Th) 1–stimulating adjuvant in P. brasiliensis–
infected mice could have a beneficial effect on the course of experimental PCM. For this purpose, mice were infected and
treated with complete Freund’s adjuvant (CFA), a well-established Th1 experimental inductor, or incomplete Freund’s
adjuvant (IFA - control group) on day 20 postinfection. Four weeks after treatment, the CFA-treated mice presented a mild
infection in the lungs characterized by absence of epithelioid cell granulomas and yeast cells, whereas the control mice
presented multiple sites of focal epithelioid granulomas with lymphomonocytic halos circumscribing a high number of
viable and nonviable yeast cells. In addition, CFA administration induced a 2.4 log reduction (.99%) in the fungal burden
when compared to the control group, and led to an improvement of immune response, reversing the immunosuppression
observed in the control group. The immunotherapy with Th1-inducing adjuvant, approved to be used in humans, might be
a valuable tool in the treatment of PCM and potentially useful to improve the clinical cure rate in humans.
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Introduction
Paracoccidioides brasiliensis is a thermally dimorphic human
pathogenic fungus that causes paracoccidioidomycosis (PCM),
the most prevalent human systemic mycosis in Latin America,
being endemic in Brazil, Argentina, Venezuela and Colombia.
This infection is acquired by inhalation of airborne propagules
found in nature, which reach the lungs and are converted to the
yeast form [1,2]. The yeasts can either be eliminated by immune-
competent cells or disseminated into tissues through lymphatic or
hematogenous routes. PCM is characterized by granulomatous
inflammation, intense immunological involvement with suppres-
sion of cellular immunity and high levels of non-protective
antibodies in serum [3]. The disease may present a broad
spectrum of clinical and pathological manifestations ranging from
asymptomatic pulmonary infection to severe and disseminated
forms [4,5]. The chronic progressive form of the disease (CF) is the
most common clinical presentation and predominantly affects
adult males, with frequent pulmonary, mucosal, cutaneous and
adrenal involvement. Although the outcome of the infection can
be due to several factors, it is especially dependent on the
protective capacity of the host immune system. The cell-mediated
immune response represents the main mechanism of defense in
PCM [1]. Conversely, it has been reported that a high level of
humoral immune response is associated with increased disease
dissemination [6].
The mechanisms underlying resistance or susceptibility to PCM
remain to be elucidated. The development of the appropriate
CD4
+ T helper (Th) subset is important for PCM resolution and
several studies have shown that different disease outcomes can be
derived from the commitment of precursors to either Th1 or Th2
lineage [7,8]. Resistance to P. brasiliensis infection has been related
to interferon-c (IFN-c) and other Th1-type cytokines [9–11], while
susceptibility has been linked to the preferential production of the
Th2-type cytokines, i.e., interleukin (IL)-4, IL-5, and IL-10 [12–
14]. Several investigators have suggested that progressive dissem-
inated forms of PCM in humans are associated with various
degrees of suppressed cell-mediated immunity [1,15,16]. This
anergy can be reversed after successful therapy, when normal
levels of T cell function are partially or completely restored [17].
The prognosis of PCM has been improved through antimycotic
drugs, however treatment regimens require an extended period of
time often associated with relapses. P. brasiliensis has the peculiarity
of responding to treatment with sulpha drugs. Nevertheless,
regimens with these agents often require extended period of
maintenance therapy that may range from months to years.
Clinically, the antifungal drugs most commonly used for PCM
include amphotericin B, sulpha derivatives and azoles, but their
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concerns, together with the elucidation of the protective immune
response against PCM have renewed interest in the development
of alternative therapeutic strategies such as immunotherapeutic
procedures, which can be useful for controlling PCM. The present
study was designed to verify if immunomodulation with CFA
could play a protective role in experimental PCM leading to a less
severe infection with decreased fungal burdens in the lungs.
Materials and Methods
Fungal isolate
Yeast cells of virulent Pb 18 strain of P. brasiliensis were cultured
at 37uC in YPD (Yeast Extract/Peptone/Dextrose) Medium
(Difco Laboratories, Detroit, USA) for 7 days and washed three
times in 0.01 M phosphate-buffered saline (PBS), pH 7?2.
Viability of yeast cells was determined by the fluorescein
diacetate-ethidium bromide treatment [20].
Mouse infection and treatment
BALB/c mice, aged 6–8 wk, were bred and maintained under
standard conditions in the animal house of the Medical School of
Ribeira ˜o Preto, University of Sa ˜o Paulo, Ribeira ˜o Preto, SP,
Brazil. All animal experiments were performed in accordance with
protocols approved by the School of Medicine of Ribeira ˜o Preto
Institutional Animal Care and Use Committee. Mice were
inoculated intravenously with 1610
6 viable yeast cells in 100 ml
of PBS. On day 20 postinfection, mice were injected subcutane-
ously with 100 ml of CFA or IFA (Sigma Chemical Co., St. Louis,
USA), both emulsified in PBS in a ratio of 1:1. Mice were killed on
day 30 after treatment and their lungs were aseptically removed.
One lung from each mouse was used for histopathology analyses
and the other for quantification of fungal burden and cytokines.
Histopathology
The lungs were fixed in 10% neutral buffered formalin for
24 hours and embedded in paraffin. Tissue sections (5 mm) were
stained with hematoxylin and eosin (H&E) or silver methenamine
(Grocott) to detect the mycotic structures using standard protocols.
Samples were analyzed by light microscopy in an Axiophot
photomicroscope (Carl Zeiss, Jena, Germany) coupled with a JVC
TK-1270 camera (Victor Company of Japan Ltd, Tokyo, Japan).
The area of individual granulomas, as well as the total area of the
lung sections and the area taken by granulomas per slide, was
measuredbycomputer-aidedimageanalysis(ImageJ1.37v,National
Institutes of Health, Bethesda, USA). The following data were thus
generated: granuloma area (mean area of all granulomas in each
lung section), granuloma relative area (% represented by total
granuloma area/total area of the lung sections) and number of
granuloma cells per area (total number of cells from a granuloma
section/the area of the respective granuloma section) of each mouse.
Quantification of colony-forming units (CFU) and
cytokines
The lungs were weighed and homogenized in 1 ml of sterile
PBS using tissue homogenizer (Ultra-Turrax T25 Basic, IKA
Works, Inc., Wilmington, USA). To determine the number of
CFU, lung homogenates were diluted 1:10 in PBS. Aliquots of
100 ml of each sample were dispensed into Petri dishes containing
brain heart infusion agar (BHI, Difco) supplemented with 4% (v/v)
of heat-inactivated fetal calf serum (FCS, Gibco BRL, Gaithers-
burg, USA). The plates were incubated at 37uC, the colonies were
counted 14 days later, and then, the number of CFU per gram of
tissue was calculated. For cytokine determination, remaining lung
homogenates were centrifuged at 5,0006g for 10 minutes and the
supernatants stored at 220uC until cytokine determination.
Supernatants were analyzed as duplicate samples from replicate
wells. A sandwich-type ELISA was used to determine IL-12, IFN-
c, TNF-a, IL-4, IL-10, and TGF-b levels, using OptEIA ELISA
kits (BD PharMingen, San Diego, USA), according to the
manufacturer’s recommendations.
Inhibition-ELISA for detection of P. brasiliensis circulating
antigen in serum
Inh-ELISA was performed as previously described [21]. Briefly,
inhibition standard curve was constructed by adding different
concentrations of P. brasiliensis gp43 (from 1 ng to 30 mg/ml) in
100 ml of normal serum and then adding 100 ml of the
standardized concentration of monoclonal antibody (MAb) anti-
gp43 (10 mg/ml). Serum samples (100 ml) were added to 100 mlo f
MAb anti-gp43. Normal serum was used as a negative control.
Polystyrene plates (Corning Costar Co., Corning, USA) were
coated with 500 ng of gp43 in 0.06 M carbonate buffer (pH 9.6)
per well (100 ml/well) overnight at 4uC. After, the plates were
blocked by incubation with 200 ml of 1% bovine serum albumin in
PBS per well for 1 h at 37uC; washed 3 times and 100 ml from
inhibition standard curve, samples and controls were added per
well and allowed to stand for 2 h at 37uC. After being washed 3
times, 100 ml of goat anti-mouse immunoglobulin G-peroxidase
(Sigma) was added, and the plates were incubated for 1 h at 37uC.
After further washings, the reaction was developed with a solution
of o-phenylenediamine (0.5 mg/ml; Sigma) and 0.005% H2O2.
The reaction was stopped with 4 N H2SO4 after 8 to 10 min of
incubation in the dark. Optical densities were measured at 490 nm
on a PowerWave X microplate reader (Bio-Tek Instruments, Inc.,
Winooski, USA). The degree of inhibition in MAb binding was
shown to be reciprocal to the concentration of circulating antigen
in the sample. The cutoff point was established as the receiver
operator characteristic (ROC) curve.
Statistical analysis
Statistical determinations of the difference between means of
experimental groups were performed using two-tailed Mann-
Author Summary
P. brasiliensis is a thermally dimorphic human pathogenic
fungus that causes paracoccidioidomycosis (PCM), the
most prevalent human systemic mycosis in Latin America,
whose drug therapy is usually prolonged and associated
with toxic side effects and relapses. Although immunosti-
mulatory therapy is a promising approach to improving the
treatment of fungal infections as PCM, few studies have
been reported. In the current study, we verified that a
single-dose administration of an adjuvant that induces T
helper (Th) 1 immune response (complete Freund’s
adjuvant [CFA]) in P. brasiliensis–infected mice was
sufficient to break the lack of immune response to the
fungus observed in infected mice. Four weeks after
treatment, the CFA-treated mice presented a mild infection
in the lungs characterized by preserved lung structure and
small fungal burden, whereas control mice that had been
treated withincomplete Freund’s adjuvant presented many
granulomatous lesions and high fungal burden. The
immunotherapy with Th1-inducing adjuvant might be a
valuable tool in the treatment of PCM and potentially
useful for faster and efficient cure of PCM in humans.
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considered to be statistically significant. All experiments were
performed at least three times.
Results/Discussion
The depression of cell-mediated immune responses has been
associated with severe PCM in humans and in the experimental
host [1,15,16,22]. However, the propensity for persistence of the
fungus in infected tissues appears to be consequence of cell-
mediated immune dysregulation with suppression of Th1 and
overexpression of Th2 responses [12–14].To evaluate whether
therapeutic immunostimulation is able to interfere in experimental
murine PCM and restore the host immune response, we selected
immunomodulators for therapy strategy based on the induction of
Th1 or Th2 immune response. Since CFA supports a Th1 status,
while incomplete Freund’s adjuvant (IFA) promotes a Th2 status
[23], BALB/c mice were divided into two groups and treated with
CFA or IFA on day 20 after infection with P. brasiliensis. The
progression of P. brasiliensis infection was determined by lung
histopathology and analysis of colony-forming unity (CFU),
parameters that are considered trustworthy to discriminate
susceptible and resistant mice to systemic fungal infection
[9,12,19,24]. At 20 days of infection the mice presented
5.8610
4 CFU/g of lung tissue (Figure 1A, dashed line) and
compact granulomas (data not shown), for this reason, this time
was chosen for the treatment regimens. On day 30 after treatment
(50 days postinfection), the lungs from IFA-treated mice presented
multiple sites of focal and confluent epithelioid granulomas with
lymphomonocytic halos circumscribing a high number of viable
and nonviable yeast cells (Figure 2A, C and E). Morphometric
analysis of the lungs from IFA-treated mice revealed a number of
granulomas of 4165.2, with a relative area of 40.766.2%. These
granulomas presented 12.261.8% of yeast cells and 660.6%
collagen (data not shown). In contrast, in the P. brasiliensis-infected
mice treated with CFA, no granulomas or yeast cells were seen in
the pulmonary sections examined and a well-preserved alveolar
architecture was observed on day 30 after treatment (Figure 2B, D
and F). Most importantly, the treatment with CFA induced a 2.4
log reduction in the fungal burden when compared to the IFA-
treated mice, corresponding to 99% less CFU (Figure 1A). The
CFU data are in agreement with the histopathology analyses,
pointing out that therapeutic immunostimulation led to an
increased clearance of fungal burden from lungs.
In order to evaluate the impact of the treatment with adjuvant,
the animals were weighed weekly until the study end point. We
observe that the animals of therapy group gained more weight
(20%) than the control group (data not shown). These results can
be correlated with a good prognostic in the PCM.
When we analyzed the production of pro and anti-inflammatory
cytokines in the supernatants of lung homogenates from the P.
brasiliensis-infected BALB/c mice treated with CFA or IFA, we
observed that the IFA-treated group produced low levels of IFN-c,
IL-4, IL-12, TNF-a, IL-10 and TGF-b (Figure 1B–G), suggesting a
suppression of the immune response in these animals. In contrast,
CFA-treated mice produced high levels of these pro and anti-
inflammatory cytokines (Figure 1B–G). Although many reports
have demonstrated that the Th2 pattern is associated with a severe
Figure 1. P. brasiliensis-infected mice treated with CFA present remarkable decrease of fungal burden and increase of cytokines
production. Mice inoculated with 1610
6 yeast cells were treated with CFA (therapy) or IFA (control) on day 20 postinfection. The lung homogenates
obtained from these mice on day 30 after treatment were analyzed for CFU (A), IFN-c (B), IL-4 (C), IL-12 (D), TNF-a (E), IL-10 (F), TGF-b (G). In the same
period the levels of P. brasiliensis circulating antigen was analyzed in serum (H). Dashed line in panel A represents the amount of viable yeasts at the
day of treatment (20 days postinfection). Data are reported as the mean6standard deviation for three mice per group performed in duplicate.
*P,0.05 compared to control group (two-tailed Mann-Whitney U-test).
doi:10.1371/journal.pntd.0000183.g001
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asymptomatic and mild forms of PCM [9–14], others have shown
that the induction of inflammatory cytokines, such as IFN-c and
TNF-a, can lead to overproduction of nitric oxide that has been
associated with suppression of cell immunity [25–27]. Recently, it
was demonstrated that the anti-inflammatory Th2 cytokine IL-4
has a dual role in PCM, leading to a protective or a disease-
promoting effect depending on the genetic background of the host
[28]. Regarding TGF-b, we observed that this cytokine is
produced by pulmonary epithelium, so we hypothesized that it
might contribute to the lung tissue renewal (unpublished data). In
this study we obtained an effective protection against P. brasiliensis
infection even in the presence of anti-inflammatory cytokines,
suggesting that, in this therapy model, the protective effect against
PCM seems to be dependent on the induction of a mixed Th1/
Th2 immune response pattern. The production of both inflam-
matory and anti-inflammatory cytokines is extremely helpful to
balance the immune response, since anti-inflammatory cytokines
can control the inflammatory responses, which can result in local
pathology and systemic and centrally controlled adverse events.
CD4
+ T cells also play a role in the regulation of inflammation
[29]. On the basis of the differences between the groups treated
with CFA or IFA, we suggest that the protection induced by CFA
injection was due to a noticeable increase in the pulmonary levels
of cytokines, which probably broke the immunosuppression status
observed in the infected mice treated with IFA. Nonetheless, we
cannot exclude the involvement of other mechanisms, such as
modulation by regulatory T cells [30], apoptosis in the antigen-
specific T cells [31], and Fas-FasL and CTLA-4 expression [32].
The levels of circulating antigen in the mice infected and treated
with IFA were two-fold higher than those treated with CFA
(Figure 1H). These results supported by other reports that showed
that the depression of cell-mediated immunity is associated with
the high levels of specific circulating antibodies or soluble antigens
in disseminated disease [13,15,21].
Although many studies on protection against PCM have been
performed, only few of them have reported the efficacy of the
immunostimulatory therapy. In one of these studies, the therapy
with peptide p10 from gp43, emulsified in CFA, and chemother-
apy was used in an attempt to improve the treatment of PCM [33].
The combined treatment showed a beneficial effect when
administered at 48 h or 30 days after challenge. However, the
control mice that received only CFA and the non-immunized mice
presented similar lung fungal burden. These data are in contrast to
those observed herein. This difference might be due to distinct
experimental protocols used, such as challenge route, dose, and
treatment regimen. Nevertheless, other reports have demonstrated
that the use of immunostimulatory therapy can lead to a positive
prognostic in fungal diseases [34–36]. Basically, therapeutic
immunostimulation can be used by reinforcing or broadening
defenses when specific immune responses are unable to do this
during the natural course of the PCM.
The present study demonstrated that a single-dose administra-
tion of the Th1-inducing adjuvant (CFA) in P. brasiliensis-infected
mice was sufficient to break the anergy observed in these animals
restoring their ability to mount an effective immune response to
the fungus. While the control mice presented large amount of
yeasts and extensive sites of parenchymal lung injury, the CFA-
treated mice were capable to control not only the fungal systemic
dissemination but also its growth, leading to a noticeable fungal
clearance without apparent lung injury. Our results indicate that
Th1-inducing adjuvant proved to be a valuable tool in the
treatment of PCM. Overall, these data open new possibilities for
the potential use of Th1-inducing adjuvant not only as a sole
therapy but also as an adjunct to conventional antifungal therapy
against PCM, improving the regular chemotherapy and reducing
the time of treatment.
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Figure 2. Therapy with CFA leads to resolution of the
pulmonary lesions in P. brasiliensis-infected mice. P. brasiliensis-
infected mice were treated with IFA (A, C and E) or CFA (B, D and F) 20
days postinfection. The lung sections obtained at day 30 after
treatment were fixed in formalin, paraffin embedded, cut into 5 mm
sections, stained with H&E (A–D) or Grocott (E and F), and analyzed by
light microscopy. Scale bars on panels A and B indicate 1 mm, on D–G
200 mm.
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